A recent report published by
Infinium Global Research on the acute migraine drugs market provides in-depth
analysis of segments and sub-segments in the global as well as regional acute
migraine drugs market. The study also highlights the impact of drivers,
restraints, and macro indicators on the global and regional acute migraine
drugs market over the short term as well as long term. The report is a
comprehensive presentation of trends, forecast and dollar values of the global
acute migraine drugs market. According to the report, the global acute migraine
drugs market is projected to reach USD 3 billion by 2027 from USD 2 billion in
2021, growing with a CAGR of 7% over the forecast period of 2021-2027.
The global migraine drugs market
exhibited strong growth during the forecast period. Migraine is known a
neurological condition that causes unilateral or throbbing pain within the
forehead, side of the pinnacle, or beside the eyes. The pain is usually because
of autonomic symptoms, like nausea, vomiting, photophobia, and phonophobia.
Migraine is usually diagnosed by examining the patient’s medical record and
symptoms, further as by performing blood tests, resonance imaging, and
computerized axial tomography scans. A major rise in the prevalence and
diagnosis of migraine represents one of the key factors bolstering the
market growth. Other than this, the development in reimbursement policies for
migraine medications, together with the escalating demand for precision
medicines, is additionally contributing to the market growth. Furthermore, the
rising demand for electrical nerve stimulating devices to treat migraine and
therefore the projected approval of recent classes of medication that are
within the late-stage pipeline and have higher clinical efficacy, like the
introduction of calcitonin gene-related peptide monoclonal antibodies, are
boosting the market growth. The testing of migraine drugs for the treatment of
coronavirus disease is anticipated to form a positive impact on the market
The rising population worldwide,
and therefore the growing demand for quality drugs are significant factors
driving the expansion of the worldwide migraine drugs market. The prevalence of
this disease is higher in women. Therefore, the growing female population
worldwide could be a big plus to the worldwide migraine drugs market expansion.
Additionally, factors like increasing work pressure, high alcohol consumption,
growing demand for quality drugs, changes in lifestyles, and awareness among
patients related to the prevention and treatment of migraine further increase
the demand levels for the world migraine drugs market. Side effects that
connect with migraine drugs are hampering the expansion of the market,
additionally, stringent rules and regulations by the govt are hindering the
expansion rate of the migraine drugs market. Also, drugs' harmful effects and
therefore the increasing precedence of other therapies restrain the expansion
during the forecast period.
Among the regions, North America
holds the biggest market share of the Acute Migraine Drugs Market. The
increasing number of patients, growing investments in R&D activities, and
the establishment of technically advanced research centers will contribute to
the Acute Migraine Drugs Market growth in the region. However, the Asia Pacific
is expected to perform the fastest growth of the Acute Migraine Drugs Market.
The rise in focus of vendors on the emerging markets, such as Asia-Pacific and
LAMEA, is expected to boost the market growth. Asia-Pacific is anticipated to
observe major growth in the forecast period, due to increasing demand for
better healthcare facilities and rising healthcare infrastructure. Furthermore,
this region presents remarkable opportunities for venture capitalists and
investors, as the developed markets are comparatively saturated.
The report on the global acute
migraine drugs market covers segments such as drug, application, and
distribution channel. On the basis of drug, the sub-markets include abortive
medicine, and preventive medicine. On the basis of application, the sub-markets
include oral, injectable, and nasal sprays. On the basis of distribution
channel, the sub-markets include hospital-based pharmacies, retail pharmacies,
and online pharmacies.
The report provides profiles of
the companies in the market such as Endo Pharmaceuticals Inc, Allergan, Impax
Laboratories, Glaxo Smith Kline, Astellas, Amgen, Bayer, AstraZeneca, Dr.
Reddy’s Laboratories, and Zogenix.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the acute migraine drugs market. Moreover, the study highlights current
market trends and provides forecast from 2021-2027. We also have highlighted
future trends in the market that will affect the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players.